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Abstract
Background Cemiplimab, a high-affinity, potent human
immunoglobulin G4 monoclonal antibody to programmed
cell death-1 demonstrated antitumor activity in a Phase
1 advanced cutaneous squamous cell carcinoma (CSCC)
expansion cohort (NCT02383212) and the pivotal Phase 2
study (NCT02760498). Here we report the primary analysis
of fixed dose cemiplimab 350 mg intravenously every 3
weeks (Q3W) (Group 3) and provide a longer-term update
after the primary analysis of weight-based cemiplimab
3 mg/kg intravenously every 2 weeks (Q2W) (Group 1)
among metastatic CSCC (mCSCC) patients in the pivotal
study (NCT02760498).
Methods The primary objective for each group was
objective response rate (ORR) per independent central
review (ICR). Secondary endpoints included ORR by
investigator review (INV), duration of response (DOR) per
ICR and INV, and safety and tolerability.
Results For Group 3 (n=56) and Group 1 (n=59), median
follow-up was 8.1 (range, 0.6 to 14.1) and 16.5 (range,
1.1 to 26.6) months, respectively. ORR per ICR was 41.1%
(95% CI, 28.1% to 55.0%) in Group 3, 49.2% (95% CI,
35.9% to 62.5%) in Group 1, and 45.2% (95% CI, 35.9%
to 54.8%) in both groups combined. Per ICR, Kaplan–
Meier estimate for DOR at 8 months was 95.0% (95% CI,
69.5% to 99. 3%) in responding patients in Group 3, and
at 12 months was 88.9% (95% CI, 69.3% to 96.3%) in
responding patients in Group 1. Per INV, ORR was 51.8%
(95% CI, 38.0% to 65.3%) in Group 3, 49.2% (95% CI,
35.9% to 62.5%) in Group 1, and 50.4% (95% CI, 41.0%
to 59.9%) in both groups combined. Overall, the most
common adverse events regardless of attribution were
fatigue (27.0%) and diarrhea (23.5%).
Conclusion In patients with mCSCC, cemiplimab 350 mg
intravenously Q3W produced substantial antitumor activity
with durable response and an acceptable safety profile.
Follow-up data of cemiplimab 3 mg/kg intravenously Q2W
demonstrate ongoing durability of responses.

Trial registration number Clinicaltrials.gov,
NCT02760498. Registered May 3, 2016, https://
clinicaltrials.gov/ct2/show/NCT02760498

Introduction
Cutaneous squamous cell carcinoma (CSCC)
is the second most common skin cancer,
and its incidence is increasing.1 2 Chronic
sun exposure, advanced age, and immunosuppression are risk factors for CSCC.3 4
Most CSCC cases are diagnosed early,5 6 and
patients with local disease are generally cured
by surgery.4 7 Conversely, the prognosis is
poor for patients with either locally advanced
CSCC (laCSCC) not amenable to curative
surgery or curative radiation or metastatic
CSCC (mCSCC), collectively referred to
as advanced CSCC, treated with cytotoxic
chemotherapy or epidermal growth factor
receptor inhibitors.8–10
Due to chronic skin damage from ultraviolet light, most CSCCs are hypermutated.11 12
Patients with high tumor mutational burden
(TMB) solid tumors are more likely to derive
clinical benefit from inhibition of immune
checkpoints, such as programmed cell death
(PD)-1.13 14 Intact immune surveillance is
critical in CSCC prevention in immunocompetent individuals, as evidenced by the
strong link between immunosuppression
and increased CSCC risk.15 16 These considerations provided rationale for the study of
PD-1 inhibition in advanced CSCC.
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Cemiplimab is a high-
affinity, highly potent human
immunoglobulin G4 monoclonal antibody to the PD-1
receptor.17 Cemiplimab demonstrated substantial antitumor activity in a Phase 1 advanced CSCC expansion
cohorts (NCT02383212) and produced an objective
response rate (ORR) per independent central review
(ICR) of 47.5% in the Phase 2 (NCT02760498) primary
analysis of the weight-based dosing cohort for patients
with mCSCC (Group 1) with emerging evidence of
durable responses.18 Supported by these findings,
cemiplimab-rwlc became the first therapy approved by the
US Food and Drug Administration for the treatment of
advanced CSCC.19 Subsequently, the European Commission granted conditional marketing authorization for
cemiplimab for the treatment of advanced CSCC.20 The
approved regimen is cemiplimab 350 mg every 3 weeks
(Q3W) intravenously.
This article presents the primary analysis of the Phase
2 study of the approved fixed dose regimen (cemiplimab
350 mg intravenously Q3W; Group 3) in patients with
mCSCC. At the time of the Group 3 primary analysis, an
additional data cut with longer follow-up was performed
in Group 1 (cemiplimab 3 mg/kg intravenously every 2
weeks (Q2W)) and reported here; results of the primary
analysis of Group 1 have been previously reported.18
Exploratory TMB analyzes are also presented.

Methods
Patients
This is an open-label, non-randomized, multicenter, international, Phase 2 study of patients with distant or nodal
mCSCC (Groups 1 and 3) (see online supplementary file
1, S1 for study sites and principal investigators). Enrollment for Group 3 opened after full enrollment of Group
1. The time point for the primary analysis of data from
patients in Group 3 was reached.
Eligible patients were aged ≥18 years with histologically
confirmed diagnosis of invasive CSCC, an Eastern Cooperative Oncology Group performance status score of 0 or
1, adequate organ function, and at least one measurable
lesion per Response Evaluation Criteria in Solid Tumors
version 1.1 (RECIST 1.1).21
Key exclusion criteria included ongoing or recent
(within 5 years) autoimmune disease requiring systemic
immunosuppression, prior treatment with an agent
blocking the PD-1/PD ligand-1 (PD-L1) pathway, a history
of solid organ transplantation, concurrent cancer (unless
indolent or non-life-threatening), or hematologic cancer.
Study design
Patients were administered cemiplimab 350 mg intravenously over 30 min Q3W for up to 54 weeks, with the
option to extend treatment to 96 weeks (Group 3) or
cemiplimab 3 mg/kg intravenously over 30 min Q2W
for up to 96 weeks (Group 1). The primary endpoint
was ORR per ICR independently in each group. Tumor
assessments were performed at the end of each treatment
2

cycle (every 9 weeks for Group 3 and every 8 weeks for
Group 1) (see online supplementary file 1, S2 for further
details).
Secondary endpoints included ORR per investigator
review (INV), duration of response (DOR) by ICR
and INV, progression-
free survival (PFS) by ICR and
INV, overall survival (OS), complete response (CR)
rate per ICR, adverse events (AEs), and quality of life.
Durable disease control rate, defined as the proportion
of patients with response or stable disease for at least
105 days was also examined. Safety assessments included
treatment-emergent AEs (TEAEs), laboratory tests, vital
signs, and physical examinations. The severity of TEAEs
was graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events
(version 4.03).
Archived tumor samples from prior CSCC biopsies or
surgeries were provided during the screening period.
TMB was estimated in DNA samples extracted from
formalin-fixed paraffin-embedded tumor biopsies. TMB
was calculated as the total number of somatic single nucleotide variants and indels in the coding regions of targeted
genes per megabase of analyzed genomic sequence (see
online supplmentary file 1, S2 for further details).
The study also includes Group 4 and pilot Group 5,
which explore alternative doses and/or schedules of
cemiplimab, and Group 6 which is designed to confirm
the results with 350 mg intravenously Q3W observed in
Group 3. Groups 4 to 6 have not reached primary analysis
and are not included in this report.
Statistical analysis
The primary endpoint analyses for each group were statistically independent. Fifty patients in each group were
needed to provide at least 85% power to reject a null
hypothesis of an ORR of 15% at a two-sided significance
level of no more than 5%, if the true ORR was 34%. The
primary efficacy analyses were undertaken using 95% binomial exact confidence intervals (CIs), which were generated using the Clopper-Pearson method.22 The secondary
efficacy analyses of DOR, PFS, and OS are summarized by
their medians and 95% CIs, which were generated by the
Kaplan–Meier method. CR rates are summarized descriptively. The full analysis set, which included all patients
who passed screening and were eligible for study participation, was used for the analysis of all efficacy endpoints.
The safety analysis set included all enrolled patients who
received any study drug. The primary efficacy analysis
of both groups was performed 6 months after the first
dose of cemiplimab had been administered to the last
patient enrolled; the results from the primary efficacy
analysis of Group 1 (cut-off date of October 27, 2017)
have been previously published.18 In the present analysis,
data are reported separately for Group 1 and Group 3,
as well as for both groups combined. The cut-off date for
the primary analysis of Group 3 and follow-up analysis of
Group 1 was September 20, 2018.
Rischin D, et al. J Immunother Cancer 2020;8:e000775. doi:10.1136/jitc-2020-000775
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Table 1 Baseline demographics and disease characteristics
Group 3
cemiplimab
350 mg intravenously Q3W
(n=56)

Group 1
cemiplimab 3 mg/kg
intravenously Q2W
(n=59)

Median age, years (range)
 <65, n (%)

71 (38 to 90)
14 (25.0)

71 (38 to 93)
16 (27.1)

71 (38 to 93)
30 (26.1)

 ≥65 to <75, n (%)

20 (35.7)

23 (39.0)

43 (37.4)

 ≥75, n (%)

22 (39.3)

20 (33.9)

42 (36.5)

Male, n (%)

48 (85.7)

54 (91.5)

102 (88.7)

 0

25 (44.6)

23 (39.0)

48 (41.7)

 1

31 (55.4)

36 (61.0)

67 (58.3)

Primary CSCC site: head and neck, n (%)

31 (55.4)

38 (64.4)

69 (60.0)

 Distant

43 (76.8)

45 (76.3)

88 (76.5)

 Nodal

12 (21.4)

14 (23.7)

26 (22.6)

Total
(Groups 1+3)
(n=115)

ECOG PS, n (%)

Metastatic status, n (%)

 Missing
Prior cancer-related systemic therapy, n (%)
Prior cancer-related radiotherapy, n (%)

1 (1.8)

0 (0.0)

1 (0.9)

20 (35.7)
38 (67.9)

33 (55.9)
50 (84.7)

53 (46.1)
88 (76.5)

CSCC, cutaneous squamous cell carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; Q2W, every 2 weeks;
Q3W, every 3 weeks.

Results
Patients
Results are presented for Group 3 primary analysis, and
for Group 1 with approximately 11 months additional
follow-up after the primary analysis. In total, 56 patients
were enrolled and treated with cemiplimab 350 mg Q3W
(Group 3) from July 2017 through March 2018, and
59 patients were enrolled and treated with cemiplimab
3 mg/kg Q2W (Group 1) from March 2016 through
January 2017. Baseline characteristics were similar in
regard to median age, gender, and extent of disease
(nodal vs distant) (table 1). The median duration of
follow-up was 8.1 (range, 0.6 to 14.1) months for Group
3 and 16.5 (range, 1.1 to 26.6) months for Group 1.
Patients in Group 3 received a median of 11.5 (range, 1 to
20) doses of cemiplimab and were exposed to treatment
for a median of 34.3 (range, 2.6 to 60.4) weeks. Patients
in Group 1 received a median of 31.0 (range, 1 to 48)
doses of cemiplimab and were exposed to treatment for a
median of 65.0 (range, 2.0 to 96.1) weeks. Patient disposition is summarized in online supplementary file 2, figure
S1.
Clinical activity
For the Group 3 primary analysis, ORR per ICR was 41.1%
(95% CI, 28.1% to 55.0%). For the Group 1 update,
ORR per ICR was 49.2% (95% CI, 35.9% to 62.5%). The
combined ORR for both groups was 45.2% (95% CI,
35.9% to 54.8%), including 39 partial responses (PRs)
and 13 CRs per ICR (table 2). The ORR per INV was
51.8% (95% CI, 38.0% to 65.3%) in Group 3 and 49.2%
Rischin D, et al. J Immunother Cancer 2020;8:e000775. doi:10.1136/jitc-2020-000775

(95% CI, 35.9% to 62.5%) in Group 1 (see online supplementary file 3, table S1).
Per ICR, most evaluable patients in both Group 3 and
Group 1 had a decrease from baseline in the target lesion
diameters (figure 1), and most responses were evident at
the first response assessment in both groups (see online
supplementary file 2, figure S2). Durable responses are
most evident in Group 1 due to longer follow-up and are
emerging for Group 3 (see online supplementary file 2,
figure S2). The median DOR had not been reached in
either group at data cut-off. Per ICR, the Kaplan–Meier
estimate for DOR at 8 months was 95.0% (95% CI,
69.5% to 99.3%) in responding patients in Group 3, and
at 12 months was 88.9% (95% CI, 69.3% to 96.3%) in
responding patients in Group 1 (table 2).
The median time to response per ICR was 2.1 (range,
2.0 to 8.3) months for Group 3, 1.9 (range, 1.7 to 9.1)
months for Group 1, and 2.1 (range, 1.7 to 9.1) months
for both groups combined. The disease control rate per
ICR was 64.3% (95% CI, 50.4% to 76.6%) in Group 3,
71.2% (95% CI, 57.9% to 82.2%) in Group 1, and 67.8%
(95% CI, 58.5% to 76.2%) in both groups combined. The
durable disease control rate per ICR was 57.1% (95% CI,
43.2% to 70.3%) in Group 3, 61.0% (95% CI, 47.4% to
73.5%) in Group 1, and 59.1% (95% CI, 49.6% to 68.2%)
in both groups combined (table 2).
Median PFS had not been reached at the time of data
cut-
off. The median Kaplan–Meier estimated PFS per
ICR was 10.4 (95% CI, 3.6 to not evaluable (NE)) months
based on 44.6% event rate for Group 3, 18.4 (95% CI,
3
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Table 2 Tumor response per independent central review
Group 3
cemiplimab
350 mg intravenously
Q3W (n=56)

Group 1
cemiplimab
Total
3 mg/kg intravenously (Groups 1+3)
Q2W (n=59)
(n=115)

ORR, % (95% CI)
Best overall response, n (%)

41.1 (28.1 to 55.0)

49.2 (35.9 to 62.5)

45.2 (35.9 to 54.8)

 Complete response

3 (5.4)

10 (16.9)

13 (11.3)

 Partial response

20 (35.7)

19 (32.2)

39 (33.9)

 Stable disease

8 (14.3)

9 (15.3)

17 (14.8)

 Non-complete response/non-progressive disease

5 (8.9)

4 (6.8)

9 (7.8)

 Progressive disease

14 (25.0)

10 (16.9)

24 (20.9)

 Not evaluable

6 (10.7)

7 (11.9)

13 (11.3)

64.3 (50.4 to 76.6)

71.2 (57.9 to 82.2)

67.8 (58.5 to 76.2)

Disease control rate, % (95% CI)
*

Durable disease control rate , % (95% CI)

57.1 (43.2 to 70.3)

61.0 (47.4 to 73.5)

59.1 (49.6 to 68.2)

Median time to response, months (range)†

2.1 (2.0 to 8.3)

1.9 (1.7 to 9.1)

2.1 (1.7 to 9.1)

Not reached

Not reached

Not reached

88.9 (69.3 to 96.3)
88.9 (69.3 to 96.3)

90.0 (75.2 to 96.2)
90.0 (75.2 to 96.2)

Median DOR
†

95.0 (69.5 to 99.3)
Kaplan–Meier 8-month estimate of DOR, % (95% CI)
Kaplan–Meier 12-month estimate of DOR, % (95% CI)† Not evaluable

Errata: after database lock, the central review vendor noted an error in their initial assessment of one patient in Group 3. This report contains
the corrected data obtained after the vendor reviewed the case again. Also, the durable disease control rate for Group 1 was updated
because one patient had tumor response after withdrawal of consent.
The ORR per investigator review was 51.8% (95% CI, 38.0% to 65.3%) in Group 3, 49.2% (95% CI, 35.9% to 62.5%) in Group 1, and 50.4%
(95% CI, 41.0% to 59.9%) in both groups combined.
*Defined as the proportion of patients without progressive disease for at least 105 days.
†Data are based on number of patients with confirmed complete or partial response.
CI, confidence interval; DOR, duration of response; DOR, duration of response; ORR, objective response rate; ORR, objective response rate;
Q2W, every 2 weeks; Q2W, every 2 weeks; Q3W, every 3 weeks; Q3W, every 3 weeks;

6.8 to NE) months based on 47.5% event rate for Group
1, and 18.4 (95% CI, 7.3 to NE) months based on 46.1%
event rate for both groups combined. The Kaplan–Meier
estimation of PFS at 12 months per ICR was 47.4% (95%
CI, 29.6% to 63.3%) for Group 3, 52.9% (95% CI, 39.0%
to 65.0%) for Group 1, and 51.2% (95% CI, 41.0% to
60.6%) for both groups combined (see online supplementary file 2, figure S3A).
Median OS had not been reached in either group at
data cut-off. The Kaplan–Meier estimation of OS at 12
months was 76.1% (95% CI, 56.9% to 87.6%) for Group 3,
81.3% (95% CI, 68.7% to 89.2%) for Group 1, and 80.7%
(95% CI, 71.9% to 87.1%) for both groups combined
(see online supplementary file 2, figure S3B).
For Group 3, ORR per ICR was explored for patients
with high body weight (>120 kg). Among four patients
who weighed >120 kg at baseline, two experienced PR per
ICR (see online supplementary file 3, table S2).
Safety
In both groups combined, 113 (98.3%) patients experienced at least one TEAE of any grade regardless of attribution, including 96.4% for Group 3% and 100.0% for
Group 1 (table 3). The most common TEAEs in Group 3,
Group 1, and both groups combined, were fatigue (28.6%,
4

25.4%, and 27.0%, respectively), diarrhea (17.9%, 28.8%,
and 23.5%, respectively), and nausea (17.9%, 23.7%, and
20.9%, respectively). Grade ≥3 TEAEs regardless of attribution were reported in 45.2% of patients in both groups
combined, with the most common in Group 3, Group 1,
and both groups combined, being anemia (8.9%, 3.4%,
and 6.1%, respectively), fatigue (5.4%, 1.7%, and 3.5%,
respectively) and pneumonitis (0.0%, 5.1%, and 2.6%)
(table 3). Treatment-related AEs (TRAEs) were reported
in 71.3% (82/115) of patients, most commonly fatigue
(13.0% (15/115)) (table 3; online supplementary file 3,
table S2). TRAEs reported in ≥5% of patients in either
treatment group are shown in online supplementary file
3, table S3. Immune-related AEs per INV are presented in
online supplementary file 3, table S4.
Three (5.4%) patients in Group 3 discontinued treatment due to an AE (Grade 3 soft tissue necrosis, n=1;
Grade 2 lethargy, n=1; and Grade 3 psoriasis, n=1). In
Group 1, six (10.2%) patients discontinued treatment
due to an AE; four of these were previously reported,18
and two occurred after the data cut for the Group 1
primary analysis. All AEs leading to treatment discontinuations were considered treatment-
related, except for
the patient in Group 3 with soft tissue necrosis on the
Rischin D, et al. J Immunother Cancer 2020;8:e000775. doi:10.1136/jitc-2020-000775
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and clinical activity of cemiplimab. Median TMBs were
61.4 and 53.2 mutations per megabase among responding
patients in Group 3 and Group 1 and were 13.7 and 19.4
mutations per megabase among non-responding patients
in Group 3 and Group 1, respectively (see online supplementary file 2, figure S4). Similar separations in median
TMB were observed among patients who achieved durable
disease control and those who did not (see online supplementary file 2, figure S5).

Figure 1 Best tumor response per RECIST 1.1 by
independent central review for (a) Group 3 and (b) Group
1. This figure shows best percent change in the sum of
tumor diameters for patients who had at least one post-
baseline radiologic assessment (39 of 56 patients in Group
3 and 45 of 59 patients in Group 1). Lesion measurements
after progression were excluded and patients who did not
have at least one post-treatment radiologic assessment of
target lesion(s) are not shown. The dashed lines indicate
RECIST 1.1 criteria for partial response (≥30% decrease in
sum of diameters) or progression (≥20% increase in sum
of diameters) of target lesions. Patients with new lesions
or unequivocal progression of non-target lesions are
considered as progressive disease (red bars) regardless of
target lesion response. Patients with a single assessment
with ≥30% reduction of target lesion(s) are considered stable
disease (blue bars) if there is not confirmatory assessment
to establish partial response. One patient in Group 1 was
not evaluable (NE) (yellow bar); this patient had radiologic
and photographic data and was, therefore, reviewed by
Independent Composite Review Committee and assessed as
NE. Patients who did not have at least one evaluable post-
baseline radiology assessment are not included in the figure
but are included in the overall response analysis (table 2) per
intention-to-treat. Increase in sum of target lesion diameters
greater than 100% is reported as 100%. RECIST 1.1,
Response Evaluation Criteria in Solid Tumors version 1.1.

head. One (1.8%) patient in Group 3 died due to arterial hemorrhage from their right lower extremity tumor
which measured 12.5 cm in longest diameter at baseline.
This death was not considered related to study treatment.
No new AEs resulting in death were reported in the
updated analysis of Group 1.
Biomarker analysis
Overall, 79 patients had pre-
treatment tumor samples
available for the analysis of associations between TMB
Rischin D, et al. J Immunother Cancer 2020;8:e000775. doi:10.1136/jitc-2020-000775

Discussion
The approved regimen of cemiplimab 350 mg intravenously Q3W (Group 3) is highly active therapy for
mCSCC (ORR per ICR, 41.1%; 95% CI 28.1% to 55.0%).
This result exceeds the prespecified statistical threshold
for clinically meaningful ORR per ICR at time of primary
analysis. The ORR per ICR for Group 1 at time of primary
analysis was 47.5%,18 and has increased to 49.2% with
longer follow-up in this report. In the combined analysis
of all mCSCC patients (Group 3 and Group 1) in this
report, ORR per ICR is 45.2%.
For the secondary endpoint of ORR per INV, numerical differences are smaller between the groups (51.8%
in Group 3, 49.2% in Group 1). Discrepancies between
ICR and INV are well described in oncology studies,23 24
and are more apparent in Group 3 than in Group 1 in
this study. Despite these differences, the 95% CIs for ORR
per ICR overlap broadly for the Group 3 primary analysis (28.1% to 55.0%) and the Group 1 update (35.9%
to 62.5%). The characteristics of responses per ICR were
similar for both groups in regard to the median time to
response (2.1 and 1.9 months in Groups 3 and 1, respectively) and durability (estimated 8-month DOR of 95.0%
and 12-month DOR of 88.9% in Groups 3 and 1, respectively). Numerical differences in point estimate of ORR
per ICR between Group 3 and Group 1 are not attributed
to differences between the two regimens, because the
fixed-based and weight-based regimens display comparable pharmacokinetics,19 and exposure to cemiplimab
in both groups was the same.25 The fixed-dose Group 3
regimen offers advantages such as a more convenient
schedule for patients and less risk of dosing error or medication wastage. Cemiplimab 350 mg Q3W intravenously is
the commercially-approved dose. Additional clinical data
regarding the fixed-dose regimen among patients with
advanced CSCC are being obtained in a confirmatory
cohort (Group 6) in this study.
The 11-month update of Group 1 illustrates hallmarks
of the potential clinical benefits of PD-1 blockade that
become apparent with longer follow-up. Almost all the
Group 1 responses illustrated in the primary analysis
report18 are still ongoing at this update (see online supplementary file 2, figure S2B). Additionally, the quality of
responses improved over time, with 10 CRs per ICR at
the 11-month update versus only four at the time of the
primary analysis.18 Because the responses are sustained,
the median DOR has yet to be reached. Therefore, the
5
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Table 3 Safety summary
Group 3
cemiplimab
350 mg intravenously Q3W
(n=56)

Group 1
cemiplimab
3 mg/kg intravenously Q2W
(n=59)

Total
(Groups 1+3)
(n=115)

Any grade

Grade ≥3

Any grade

Grade ≥3

Any grade

Grade ≥3

22 (39.3)

59 (100.0)

30 (50.8)

113 (98.3)

52 (45.2)

2 (3.6)

6 (10.2)

4 (6.8)

9 (7.8)

6 (5.2)

Any TEAE, regardless of
54 (96.4)
attribution
TEAEs, regardless of attribution, 3 (5.4)
that led to discontinuation
Most common TEAEs*, regardless of attribution
Fatigue

16 (28.6)

3 (5.4)

15 (25.4)

1 (1.7)

31 (27.0)

4 (3.5)

Diarrhea

10 (17.9)

0 (0.0)

17 (28.8)

1 (1.7)

27 (23.5)

1 (0.9)

Nausea

10 (17.9)

0 (0.0)

14 (23.7)

0 (0.0)

24 (20.9)

0 (0.0)

Rash

9 (16.1)

0 (0.0)

10 (16.9)

0 (0.0)

19 (16.5)

0 (0.0)

Constipation

7 (12.5)

0 (0.0)

10 (16.9)

1 (1.7)

17 (14.8)

1 (0.9)

Pruritus

6 (10.7)

0 (0.0)

10 (16.9)

0 (0.0)

16 (13.9)

0 (0.0)

Maculopapular rash

7 (12.5)

1 (1.8)

8 (13.6)

0 (0.0)

15 (13.0)

1 (0.9)

Anemia

7 (12.5)

5 (8.9)

7 (11.9)

2 (3.4)

14 (12.2)

7 (6.1)

Arthralgia

5 (8.9)

0 (0.0)

9 (15.3)

0 (0.0)

14 (12.2)

0 (0.0)

Cough

4 (7.1)

0 (0.0)

9 (15.3)

0 (0.0)

13 (11.3)

0 (0.0)

Headache

2 (3.6)

0 (0.0)

11 (18.6)

0 (0.0)

13 (11.3)

0 (0.0)

Decreased appetite

4 (7.1)

0 (0.0)

8 (13.6)

0 (0.0)

12 (10.4)

0 (0.0)

Hypothyroidism

6 (10.7)

0 (0.0)

6 (10.2)

0 (0.0)

12 (10.4)

0 (0.0)

Vomiting

6 (10.7)

0 (0.0)

6 (10.2)

0 (0.0)

12 (10.4)

0 (0.0)

Peripheral edema

6 (10.7)

0 (0.0)

4 (6.8)

0 (0.0)

10 (8.7)

0 (0.0)

Upper respiratory tract infection

3 (5.4)

0 (0.0)

6 (10.2)

0 (0.0)

9 (7.8)

0 (0.0)

Dizziness

1 (1.8)

0 (0.0)

7 (11.9)

0 (0.0)

8 (7.0)

0 (0.0)

Dry skin

2 (3.6)

0 (0.0)

6 (10.2)

0 (0.0)

8 (7.0)

0 (0.0)

Pneumonitis

2 (3.6)

0 (0.0)

6 (10.2)

3 (5.1)

8 (7.0)

3 (2.6)

Dyspnea

1 (1.8)

0 (0.0)

6 (10.2)

2 (3.4)

7 (6.1)

2 (1.7)

Oropharyngeal pain
Treatment-related†

0 (0.0)
36 (64.3)

0 (0.0)
7 (12.5)

6 (10.2)
46 (78.0)

0 (0.0)
9 (15.3)

6 (5.2)
82 (71.3)

0 (0.0)
16 (13.9)

Data are number of patients (%).
*Adverse events reported in ≥10% of patients in either treatment group are presented, ordered by frequency in both groups combined.
†See online supplement for additional details on treatment-related adverse events.
Q2W, every 2 weeks; Q3W, every 3 weeks; TEAEs, treatment-emergent adverse events.

protocol has been amended to allow another year of
active follow-
up with centrally reviewed imaging after
completion of planned therapy. Patients in both groups
continued in active follow-up after the data cut for this
article, and long-term data continues to be collected so
that the tail of the curve regarding survival and response
duration can be more fully characterized in these groups.
Most TRAEs in both groups were Grades 1 to 2 and the
discontinuation rate was low, regardless of attribution.
The TEAE profile here is comparable to that of PD-1
checkpoint inhibitors pembrolizumab and nivolumab in
patients with other cancer types such as head and neck
squamous cell cancer.26 27 A larger proportion of patients
in the present analyses was aged at least 75 years (36.5%
6

vs 6.3% in pembrolizumab and 5.0% in nivolumab).26 27
The results presented here indicate that the safety profile
with the anti–PD-1 class is not markedly different between
younger and older patients. Overall, the safety profile for
cemiplimab in this article continues to be consistent with
that which has been reported for other anti–PD-1/PD-L1
inhibitors.28
As data accumulate regarding the treatment of
advanced CSCC patients with cemiplimab, the distinctions from results obtained in earlier studies of conventional therapies become clearer. This includes studies
of cytotoxic chemotherapy and epidermal growth factor
receptor-targeted therapy.6 7 Durable responses to these
agents are not common, and the TEAEs associated
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with these therapies can be difficult to manage among
older patients with advanced CSCC. Although there
are currently no clinical trials directly comparing cemiplimab with these therapies, and the study design of
the conventional therapies are different from that of
cemiplimab, the differences in efficacy, durability of
response, and safety position highlight cemiplimab as
the standard of care for patients with advanced CSCC.
In recent congress proceedings, pembrolizumab
demonstrated ORR of 34.3% (n=105; median follow-up
of 9.5 months) in patients with recurrent/mCSCC.29
These data further support the clinical activity of PD-1
checkpoint inhibitors in advanced CSCC.
Higher median TMB was observed among responding
patients than among non-responding patients in both
Groups 3 and 1. Similar results were observed in exploratory analyses of laCSCC patients in Group 2.30 However,
high TMB among some non-responders and low TMB
among some responders preclude this assay from use as
a patient selection tool. Future prospective data sets that
integrate baseline TMB with other candidate biomarkers
or clinical prognostic factors may better define features
associated with clinical benefit among patients with
advanced CSCC treated with cemiplimab.
In conclusion, cemiplimab 350 mg intravenously
Q3W produced substantial antitumor activity. Durable
responses have been observed in both weight-based and
fixed-dosing groups. The safety profile was similar in both
groups. Long-term follow-up of these patients is ongoing.
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